JP2012521358A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012521358A5 JP2012521358A5 JP2012500998A JP2012500998A JP2012521358A5 JP 2012521358 A5 JP2012521358 A5 JP 2012521358A5 JP 2012500998 A JP2012500998 A JP 2012500998A JP 2012500998 A JP2012500998 A JP 2012500998A JP 2012521358 A5 JP2012521358 A5 JP 2012521358A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- independently
- formulation
- compound according
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 claims description 10
- 230000008685 targeting Effects 0.000 claims description 8
- 229910052757 nitrogen Inorganic materials 0.000 claims description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 5
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims description 3
- 229910052760 oxygen Inorganic materials 0.000 claims description 3
- 239000001301 oxygen Substances 0.000 claims description 3
- 150000001875 compounds Chemical class 0.000 claims 11
- 238000009472 formulation Methods 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 210000004027 cell Anatomy 0.000 claims 3
- 108090000623 proteins and genes Proteins 0.000 claims 3
- 108091023037 Aptamer Proteins 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- 108020004459 Small interfering RNA Proteins 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims 2
- 235000018102 proteins Nutrition 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 150000003384 small molecules Chemical class 0.000 claims 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 1
- PYSRRFNXTXNWCD-UHFFFAOYSA-N 3-(2-phenylethenyl)furan-2,5-dione Chemical compound O=C1OC(=O)C(C=CC=2C=CC=CC=2)=C1 PYSRRFNXTXNWCD-UHFFFAOYSA-N 0.000 claims 1
- WHNPOQXWAMXPTA-UHFFFAOYSA-N 3-methylbut-2-enamide Chemical compound CC(C)=CC(N)=O WHNPOQXWAMXPTA-UHFFFAOYSA-N 0.000 claims 1
- 102000053642 Catalytic RNA Human genes 0.000 claims 1
- 108090000994 Catalytic RNA Proteins 0.000 claims 1
- 229920002307 Dextran Polymers 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 239000004372 Polyvinyl alcohol Substances 0.000 claims 1
- 108091027967 Small hairpin RNA Proteins 0.000 claims 1
- 229920000147 Styrene maleic anhydride Polymers 0.000 claims 1
- 230000000692 anti-sense effect Effects 0.000 claims 1
- 239000002981 blocking agent Substances 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 230000010261 cell growth Effects 0.000 claims 1
- 210000000170 cell membrane Anatomy 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 claims 1
- 210000001163 endosome Anatomy 0.000 claims 1
- 230000000799 fusogenic effect Effects 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 108020004999 messenger RNA Proteins 0.000 claims 1
- 108091070501 miRNA Proteins 0.000 claims 1
- 239000002679 microRNA Substances 0.000 claims 1
- 108020004707 nucleic acids Proteins 0.000 claims 1
- 102000039446 nucleic acids Human genes 0.000 claims 1
- 150000007523 nucleic acids Chemical class 0.000 claims 1
- 125000002811 oleoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 239000008191 permeabilizing agent Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 229920001562 poly(N-(2-hydroxypropyl)methacrylamide) Polymers 0.000 claims 1
- 229920002401 polyacrylamide Polymers 0.000 claims 1
- 229920002643 polyglutamic acid Polymers 0.000 claims 1
- 108091033319 polynucleotide Proteins 0.000 claims 1
- 102000040430 polynucleotide Human genes 0.000 claims 1
- 239000002157 polynucleotide Substances 0.000 claims 1
- 229920002451 polyvinyl alcohol Polymers 0.000 claims 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108020004418 ribosomal RNA Proteins 0.000 claims 1
- 108091092562 ribozyme Proteins 0.000 claims 1
- 239000004055 small Interfering RNA Substances 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
- 239000011782 vitamin Substances 0.000 claims 1
- 229940088594 vitamin Drugs 0.000 claims 1
- 229930003231 vitamin Natural products 0.000 claims 1
- 235000013343 vitamin Nutrition 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US16182809P | 2009-03-20 | 2009-03-20 | |
| US61/161,828 | 2009-03-20 | ||
| PCT/US2010/028000 WO2010108108A2 (en) | 2009-03-20 | 2010-03-19 | Polyamine derivatives |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015018143A Division JP6190401B2 (ja) | 2009-03-20 | 2015-02-02 | ポリアミン誘導体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012521358A JP2012521358A (ja) | 2012-09-13 |
| JP2012521358A5 true JP2012521358A5 (enExample) | 2014-10-16 |
| JP5782602B2 JP5782602B2 (ja) | 2015-09-24 |
Family
ID=42359538
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012500998A Active JP5782602B2 (ja) | 2009-03-20 | 2010-03-19 | ポリアミン誘導体 |
| JP2015018143A Active JP6190401B2 (ja) | 2009-03-20 | 2015-02-02 | ポリアミン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015018143A Active JP6190401B2 (ja) | 2009-03-20 | 2015-02-02 | ポリアミン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (4) | US8460696B2 (enExample) |
| EP (1) | EP2414322B1 (enExample) |
| JP (2) | JP5782602B2 (enExample) |
| KR (2) | KR101800833B1 (enExample) |
| CN (2) | CN102438978B (enExample) |
| AU (1) | AU2010226434A1 (enExample) |
| CA (1) | CA2755963C (enExample) |
| ES (1) | ES2931174T3 (enExample) |
| PT (1) | PT2414322T (enExample) |
| WO (1) | WO2010108108A2 (enExample) |
Families Citing this family (101)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2941152B1 (fr) * | 2009-01-20 | 2013-10-18 | Centre Nat Rech Scient | Vecteurs comprenant une macromolecule anionique et un lipide cationique pour l'administration de petits acides nucleiques. |
| AU2010226434A1 (en) | 2009-03-20 | 2011-10-13 | Egen, Inc. | Polyamine derivatives |
| CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| ES3005233T3 (en) | 2010-10-01 | 2025-03-14 | Modernatx Inc | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2014508102A (ja) | 2010-11-15 | 2014-04-03 | ライフ テクノロジーズ コーポレーション | アミン含有トランスフェクション試薬ならびにそれを生成および使用するための方法 |
| US20120202890A1 (en) * | 2011-02-08 | 2012-08-09 | Nian Wu | Polymer-carbohydrate-lipid conjugates |
| JP2014511687A (ja) | 2011-03-31 | 2014-05-19 | モデルナ セラピューティクス インコーポレイテッド | 工学操作された核酸の送達および製剤 |
| AU2012242455A1 (en) | 2011-04-15 | 2013-11-28 | Molecular Transfer, Inc. | Agents for improved delivery of nucleic acids to eukaryotic cells |
| US8883177B2 (en) * | 2011-06-28 | 2014-11-11 | Nian Wu | Pharmaceutical compositions for parenteral administration |
| US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
| EP2763701B1 (en) | 2011-10-03 | 2018-12-19 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
| JP2015501844A (ja) | 2011-12-16 | 2015-01-19 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 修飾ヌクレオシド、ヌクレオチドおよび核酸組成物 |
| US9254311B2 (en) | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| CN108949772A (zh) | 2012-04-02 | 2018-12-07 | 现代泰克斯公司 | 用于产生与人类疾病相关的生物制剂和蛋白质的修饰多核苷酸 |
| WO2013151663A1 (en) | 2012-04-02 | 2013-10-10 | modeRNA Therapeutics | Modified polynucleotides for the production of membrane proteins |
| US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
| US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
| ES2921623T3 (es) | 2012-11-26 | 2022-08-30 | Modernatx Inc | ARN modificado terminalmente |
| JP2016504050A (ja) | 2013-01-17 | 2016-02-12 | モデルナ セラピューティクス インコーポレイテッドＭｏｄｅｒｎａ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． | 細胞表現型の改変のためのシグナルセンサーポリヌクレオチド |
| US20160024181A1 (en) | 2013-03-13 | 2016-01-28 | Moderna Therapeutics, Inc. | Long-lived polynucleotide molecules |
| US10258698B2 (en) | 2013-03-14 | 2019-04-16 | Modernatx, Inc. | Formulation and delivery of modified nucleoside, nucleotide, and nucleic acid compositions |
| US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
| WO2014148378A1 (ja) * | 2013-03-19 | 2014-09-25 | 公立大学法人首都大学東京 | 界面活性剤様化合物 |
| MX2016000021A (es) | 2013-07-05 | 2017-04-06 | Bioneer Corp | Sirna virus especifico del dengue, estructura arn oligo helicoidal, y composicion para la supresion de proliferacion del virus del dengue que comprende la estructura arn. |
| EP3591053A1 (en) * | 2013-07-05 | 2020-01-08 | Bioneer Corporation | Respiratory disease-related gene specific sirna, double-helical oligo rna structure containing sirna, compositon containing same for preventing or treating respiratory disease |
| MX378462B (es) | 2013-07-05 | 2025-03-10 | Bioneer Corp | Estructura de nanoparticula del tipo oligonuclèotido mejorada que tiene alta eficiencia y mètodo para preparar la misma. |
| HUE056760T2 (hu) | 2013-07-11 | 2022-03-28 | Modernatx Inc | A CRISPR-hez kapcsolódó fehérjéket és a szintetikus SGRNS-ket kódoló szintetikus polinukleotidokat tartalmazó készítmények és felhasználási módjaik |
| WO2015034925A1 (en) | 2013-09-03 | 2015-03-12 | Moderna Therapeutics, Inc. | Circular polynucleotides |
| US20160194625A1 (en) | 2013-09-03 | 2016-07-07 | Moderna Therapeutics, Inc. | Chimeric polynucleotides |
| WO2015048744A2 (en) | 2013-09-30 | 2015-04-02 | Moderna Therapeutics, Inc. | Polynucleotides encoding immune modulating polypeptides |
| KR20160067219A (ko) | 2013-10-03 | 2016-06-13 | 모더나 세라퓨틱스, 인코포레이티드 | 저밀도 지단백질 수용체를 암호화하는 폴리뉴클레오타이드 |
| KR101647178B1 (ko) * | 2013-11-28 | 2016-08-23 | 충남대학교산학협력단 | 효소 절단성 링커 또는 올리고 라이신을 포함하는 폴리에틸렌글리콜-리피드를 이용한 안정화된 플라스미드-지질 입자 |
| EP3082760A1 (en) | 2013-12-19 | 2016-10-26 | Novartis AG | LEPTIN mRNA COMPOSITIONS AND FORMULATIONS |
| US10208309B2 (en) | 2014-04-04 | 2019-02-19 | Bioneer Corporation | Double-stranded oligo RNA targeted to amphiregulin and pharmaceutical composition comprising same for preventing or treating fibrosis or respiratory diseases |
| DK3134131T3 (en) | 2014-04-23 | 2022-02-07 | Modernatx Inc | Nucleic acid vaccines |
| CA2952824C (en) * | 2014-06-24 | 2023-02-21 | Shire Human Genetic Therapies, Inc. | Stereochemically enriched compositions for delivery of nucleic acids |
| EP3169693B1 (en) | 2014-07-16 | 2022-03-09 | ModernaTX, Inc. | Chimeric polynucleotides |
| WO2016014846A1 (en) | 2014-07-23 | 2016-01-28 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of intrabodies |
| WO2016122791A1 (en) * | 2015-01-30 | 2016-08-04 | The Regents Of The University Of California | Spinal subpial gene delivery system |
| RS63030B1 (sr) | 2015-09-17 | 2022-04-29 | Modernatx Inc | Jedinjenja i kompozicije za intracelularno isporučivanje terapeutskih sredstava |
| CA3007955A1 (en) | 2015-12-10 | 2017-06-15 | Modernatx, Inc. | Lipid nanoparticles for delivery of therapeutic agents |
| JP7114465B2 (ja) | 2015-12-22 | 2022-08-08 | モデルナティエックス インコーポレイテッド | 薬剤の細胞内送達のための化合物および組成物 |
| US11583504B2 (en) | 2016-11-08 | 2023-02-21 | Modernatx, Inc. | Stabilized formulations of lipid nanoparticles |
| ES3020935T3 (en) | 2017-03-15 | 2025-05-23 | Modernatx Inc | Lipid nanoparticle formulation |
| KR20190132405A (ko) | 2017-03-15 | 2019-11-27 | 모더나티엑스, 인크. | 치료제의 세포내 전달을 위한 화합물 및 조성물 |
| CA3056133A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Crystal forms of amino lipids |
| US11421011B2 (en) | 2017-05-18 | 2022-08-23 | Modernatx, Inc. | Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof |
| ES2952779T3 (es) | 2017-05-18 | 2023-11-06 | Modernatx Inc | ARN mensajero modificado que comprende elementos de ARN funcionales |
| EP3638292A1 (en) | 2017-06-14 | 2020-04-22 | ModernaTX, Inc. | Polynucleotides encoding coagulation factor viii |
| US12077501B2 (en) | 2017-06-14 | 2024-09-03 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of agents |
| WO2018232357A1 (en) | 2017-06-15 | 2018-12-20 | Modernatx, Inc. | Rna formulations |
| WO2019046809A1 (en) | 2017-08-31 | 2019-03-07 | Modernatx, Inc. | METHODS OF MANUFACTURING LIPID NANOPARTICLES |
| EP4219715A3 (en) | 2017-09-08 | 2023-09-06 | MiNA Therapeutics Limited | Stabilized cebpa sarna compositions and methods of use |
| JP7424976B2 (ja) | 2017-11-22 | 2024-01-30 | モダーナティエックス・インコーポレイテッド | プロピオン酸血症の治療用のプロピオニルＣｏＡカルボキシラーゼアルファ及びベータサブユニットをコードするポリヌクレオチド |
| WO2019104160A2 (en) | 2017-11-22 | 2019-05-31 | Modernatx, Inc. | Polynucleotides encoding phenylalanine hydroxylase for the treatment of phenylketonuria |
| EP3714048B1 (en) | 2017-11-22 | 2025-04-09 | ModernaTX, Inc. | Polynucleotides encoding ornithine transcarbamylase for the treatment of urea cycle disorders |
| EP3735270A1 (en) | 2018-01-05 | 2020-11-11 | Modernatx, Inc. | Polynucleotides encoding anti-chikungunya virus antibodies |
| KR102056144B1 (ko) | 2018-03-08 | 2019-12-16 | 주식회사 파마리서치프로덕트 | Dna 단편 혼합물이 고농도로 함유된 유동성을 갖는 액제 조성물 및 이의 제조방법 |
| EP4242307A3 (en) | 2018-04-12 | 2023-12-27 | MiNA Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| US20210346306A1 (en) | 2018-05-23 | 2021-11-11 | Modernatx, Inc. | Delivery of dna |
| US20220184185A1 (en) | 2018-07-25 | 2022-06-16 | Modernatx, Inc. | Mrna based enzyme replacement therapy combined with a pharmacological chaperone for the treatment of lysosomal storage disorders |
| US20210317461A1 (en) | 2018-08-09 | 2021-10-14 | Verseau Therapeutics, Inc. | Oligonucleotide compositions for targeting ccr2 and csf1r and uses thereof |
| WO2020047201A1 (en) | 2018-09-02 | 2020-03-05 | Modernatx, Inc. | Polynucleotides encoding very long-chain acyl-coa dehydrogenase for the treatment of very long-chain acyl-coa dehydrogenase deficiency |
| EP3849595B1 (en) | 2018-09-13 | 2025-11-19 | ModernaTX, Inc. | Polynucleotides encoding glucose-6-phosphatase for the treatment of glycogen storage disease |
| WO2020056155A2 (en) | 2018-09-13 | 2020-03-19 | Modernatx, Inc. | Polynucleotides encoding branched-chain alpha-ketoacid dehydrogenase complex e1-alpha, e1-beta, and e2 subunits for the treatment of maple syrup urine disease |
| US20220401584A1 (en) | 2018-09-14 | 2022-12-22 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| US12151029B2 (en) | 2018-09-19 | 2024-11-26 | Modernatx, Inc. | PEG lipids and uses thereof |
| WO2020061367A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Compounds and compositions for intracellular delivery of therapeutic agents |
| AU2019345067A1 (en) | 2018-09-19 | 2021-04-08 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| EP3856233A1 (en) | 2018-09-27 | 2021-08-04 | Modernatx, Inc. | Polynucleotides encoding arginase 1 for the treatment of arginase deficiency |
| WO2020208361A1 (en) | 2019-04-12 | 2020-10-15 | Mina Therapeutics Limited | Sirt1-sarna compositions and methods of use |
| CN114375190A (zh) | 2019-05-08 | 2022-04-19 | 阿斯利康(瑞典)有限公司 | 用于皮肤和伤口的组合物及其使用方法 |
| CA3155015A1 (en) | 2019-09-19 | 2021-03-25 | Modernatx, Inc. | Carbonate containing lipid compounds and compositions for intracellular delivery of therapeutic agents |
| MX2022003269A (es) | 2019-09-19 | 2022-07-04 | Modernatx Inc | Compuestos lipidicos de cola ramificada y composiciones para la administracion intracelular de agentes terapeuticos. |
| CA3184474A1 (en) | 2020-06-01 | 2021-12-09 | Modernatx, Inc. | Phenylalanine hydroxylase variants and uses thereof |
| WO2022104131A1 (en) | 2020-11-13 | 2022-05-19 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| US11524023B2 (en) | 2021-02-19 | 2022-12-13 | Modernatx, Inc. | Lipid nanoparticle compositions and methods of formulating the same |
| WO2022204390A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding phenylalanine hydroxylase and uses thereof |
| US20240226025A1 (en) | 2021-03-24 | 2024-07-11 | Modernatx, Inc. | Polynucleotides encoding methylmalonyl-coa mutase for the treatment of methylmalonic acidemia |
| WO2022204370A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles and polynucleotides encoding ornithine transcarbamylase for the treatment of ornithine transcarbamylase deficiency |
| WO2022204371A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding glucose-6-phosphatase and uses thereof |
| WO2022204380A1 (en) | 2021-03-24 | 2022-09-29 | Modernatx, Inc. | Lipid nanoparticles containing polynucleotides encoding propionyl-coa carboxylase alpha and beta subunits and uses thereof |
| CA3214137A1 (en) | 2021-03-26 | 2022-09-29 | Mina Therapeutics Limited | Tmem173 sarna compositions and methods of use |
| US20240384277A1 (en) | 2021-06-15 | 2024-11-21 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| US20240376445A1 (en) | 2021-06-22 | 2024-11-14 | Modernatx, Inc. | Polynucleotides encoding uridine diphosphate glycosyltransferase 1 family, polypeptide a1 for the treatment of crigler-najjar syndrome |
| WO2023056044A1 (en) | 2021-10-01 | 2023-04-06 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of fibrosis and/or cardiovascular disease |
| WO2023099884A1 (en) | 2021-12-01 | 2023-06-08 | Mina Therapeutics Limited | Pax6 sarna compositions and methods of use |
| KR102852074B1 (ko) * | 2021-12-23 | 2025-08-28 | 주식회사 삼양홀딩스 | 약물 전달용 지질 및 이를 포함하는 나노입자, 및 이 나노입자를 포함하는 약물 전달용 조성물 |
| KR102927154B1 (ko) * | 2021-12-23 | 2026-02-12 | (주)삼양바이오팜 | 약물의 폐 전달용 나노입자 조성물 |
| WO2023170435A1 (en) | 2022-03-07 | 2023-09-14 | Mina Therapeutics Limited | Il10 sarna compositions and methods of use |
| WO2023183909A2 (en) | 2022-03-25 | 2023-09-28 | Modernatx, Inc. | Polynucleotides encoding fanconi anemia, complementation group proteins for the treatment of fanconi anemia |
| MA71619A (fr) | 2022-07-26 | 2025-05-30 | Modernatx, Inc. | Polynucléotides modifiés pour la régulation temporelle de l'expression |
| AU2023329397A1 (en) * | 2022-08-26 | 2025-03-06 | Renagade Therapeutics Management Inc. | Pegylated lipid compounds and methods of use thereof |
| WO2024125597A1 (en) | 2022-12-14 | 2024-06-20 | Providence Therapeutics Holdings Inc. | Compositions and methods for infectious diseases |
| WO2024134199A1 (en) | 2022-12-22 | 2024-06-27 | Mina Therapeutics Limited | Chemically modified sarna compositions and methods of use |
| WO2024197033A1 (en) | 2023-03-21 | 2024-09-26 | Modernatx, Inc. | Polynucleotides encoding relaxin for the treatment of heart failure |
| AU2024265267A1 (en) | 2023-05-03 | 2025-11-20 | Modernatx, Inc. | Polynucleotides encoding cystic fibrosis transmembrane conductance regulator for the treatment of cystic fibrosis |
| WO2025072482A1 (en) | 2023-09-27 | 2025-04-03 | Modernatx, Inc. | Immunoglobulin a protease polypeptides, polynucleotides, and uses thereof |
| WO2025255199A1 (en) | 2024-06-05 | 2025-12-11 | Modernatx, Inc. | Argininosuccinate synthase 1 and argininosuccinate lyase polypeptides and polynucleotides and uses thereof |
| WO2026027887A2 (en) | 2024-08-02 | 2026-02-05 | Mina Therapeutics Limited | Hbg1/2-sarna compositions and methods of use |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2580880A (en) | 1942-03-27 | 1952-01-01 | Nat Aluminate Corp | Prevention of foaming in steam generation |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| WO1989008098A2 (en) | 1988-02-19 | 1989-09-08 | The Upjohn Company | Lipophilic polyamines useful for treating hypercholesterolemia |
| JP2610752B2 (ja) * | 1992-07-02 | 1997-05-14 | 花王株式会社 | 新規ジアミドアミン及びその製造法 |
| JPH06345704A (ja) | 1993-06-04 | 1994-12-20 | Lion Corp | 新規なジアミドアミン化合物、その中間体及びその製造方法と柔軟剤 |
| ATE301201T1 (de) | 1993-06-07 | 2005-08-15 | Vical Inc | Für die gentherapie verwendbare plasmide |
| JPH0718569A (ja) * | 1993-06-29 | 1995-01-20 | Lion Corp | 柔軟剤組成物 |
| JPH0718571A (ja) * | 1993-06-29 | 1995-01-20 | Lion Corp | 柔軟剤組成物 |
| DE4425857A1 (de) * | 1994-07-07 | 1996-01-11 | Schering Ag | Kaskaden-Polymer-Komplexe, Verfahren zur ihrer Herstellung und diese enthaltende pharmazeutische Mittel |
| US5962428A (en) | 1995-03-30 | 1999-10-05 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| JPH101869A (ja) | 1996-06-12 | 1998-01-06 | Lion Corp | 液体柔軟剤組成物 |
| DE69735292T2 (de) * | 1996-10-25 | 2006-10-19 | Gilead Sciences, Inc., Foster City | Gefaesszellen wachstumsfaktor (vegf) nukleinsäureligand-komplexe |
| JP2001525470A (ja) * | 1997-12-12 | 2001-12-11 | マクロメド・インコーポレーテッド | タンパク修飾のためのヘテロ官能化星形ポリ（エチレングリコール） |
| AUPP249298A0 (en) | 1998-03-20 | 1998-04-23 | Ag-Gene Australia Limited | Synthetic genes and genetic constructs comprising same I |
| US6656498B1 (en) * | 1998-11-25 | 2003-12-02 | Vanderbilt University | Cationic liposomes for gene transfer |
| EP1513538A4 (en) * | 2002-06-14 | 2007-08-22 | Mirus Bio Corp | Novel methods for introducing polynucleotides into cells |
| SG190613A1 (en) * | 2003-07-16 | 2013-06-28 | Protiva Biotherapeutics Inc | Lipid encapsulated interfering rna |
| CN1882693B (zh) * | 2003-09-15 | 2012-08-15 | 普洛体维生物治疗公司 | 聚乙二醇修饰的脂质化合物及其应用 |
| US20050095280A1 (en) * | 2003-10-15 | 2005-05-05 | Michalakis Savva | Single-component pH-sensitive liposomes of reduced solid-to-liquid phase transition temperatures |
| JP4884231B2 (ja) * | 2004-11-02 | 2012-02-29 | 公益財団法人新産業創造研究機構 | コネキシン２６阻害活性を有する多量体型オレアミド誘導体と、その癌治療等への利用 |
| BRPI0608172B1 (pt) * | 2005-04-15 | 2016-07-19 | Basf Ag | polialquilenimina alcoxilada solúvel em água anfifílica |
| EP1776943B1 (en) * | 2005-10-20 | 2011-12-14 | Dentsply DeTrey GmbH | Dental adhesive |
| WO2008042973A2 (en) * | 2006-10-03 | 2008-04-10 | Alnylam Pharmaceuticals, Inc. | Lipid containing formulations |
| EP1955712A1 (en) * | 2007-02-09 | 2008-08-13 | Scil proteins GmbH | Multimeric conjugate |
| AU2010226434A1 (en) | 2009-03-20 | 2011-10-13 | Egen, Inc. | Polyamine derivatives |
-
2010
- 2010-03-19 AU AU2010226434A patent/AU2010226434A1/en not_active Abandoned
- 2010-03-19 ES ES10709947T patent/ES2931174T3/es active Active
- 2010-03-19 KR KR1020117024770A patent/KR101800833B1/ko not_active Expired - Fee Related
- 2010-03-19 CN CN201080022046.3A patent/CN102438978B/zh active Active
- 2010-03-19 KR KR1020177033391A patent/KR101906392B1/ko active Active
- 2010-03-19 CN CN201510146197.4A patent/CN104922676B/zh active Active
- 2010-03-19 EP EP10709947.5A patent/EP2414322B1/en active Active
- 2010-03-19 US US12/727,987 patent/US8460696B2/en active Active
- 2010-03-19 CA CA2755963A patent/CA2755963C/en active Active
- 2010-03-19 JP JP2012500998A patent/JP5782602B2/ja active Active
- 2010-03-19 PT PT107099475T patent/PT2414322T/pt unknown
- 2010-03-19 WO PCT/US2010/028000 patent/WO2010108108A2/en not_active Ceased
-
2013
- 2013-03-08 US US13/791,102 patent/US8932638B2/en active Active
- 2013-03-08 US US13/790,980 patent/US8900621B2/en active Active
-
2014
- 2014-12-18 US US14/575,555 patent/US9254334B2/en active Active
-
2015
- 2015-02-02 JP JP2015018143A patent/JP6190401B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Haussecker | Current issues of RNAi therapeutics delivery and development | |
| JP2021531022A5 (enExample) | ||
| US20190038557A1 (en) | Means for lung specific delivery | |
| Carmona et al. | Controlling HBV replication in vivo by intravenous administration of triggered PEGylated siRNA-nanoparticles | |
| Truong et al. | An influenza virus-inspired polymer system for the timed release of siRNA | |
| Patil et al. | Internally cationic polyamidoamine PAMAM-OH dendrimers for siRNA delivery: effect of the degree of quaternization and cancer targeting | |
| Merkel et al. | Nonviral siRNA delivery to the lung: Investigation of PEG− PEI polyplexes and their in vivo performance | |
| Qin et al. | RGD peptide-based lipids for targeted mRNA delivery and gene editing applications | |
| US20070218122A1 (en) | siRNA silencing of influenza virus gene expression | |
| US20140315795A1 (en) | Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types | |
| CN117017939A (zh) | 脂质纳米颗粒及包含其的药物组合物 | |
| US10030243B2 (en) | Nanoparticle type oligonucleotide structure having high efficiency and method for preparing same | |
| CN116744979A (zh) | 包含甘露糖的脂质纳米颗粒或其应用 | |
| Li et al. | Co-delivery of dexamethasone and a microRNA-155 inhibitor using dendrimer-entrapped gold nanoparticles for acute lung injury therapy | |
| JP2012505250A5 (enExample) | ||
| WO2008118013A3 (en) | Targeted intracellular delivery of antiviral agents | |
| CN107001627A (zh) | 用于将核酸引入细胞的组合物 | |
| JP2021525508A (ja) | 核酸治療薬のための調節可能な共カップリングポリペプチドナノ粒子送達系の組成物および方法 | |
| US20220143197A1 (en) | siRNA Inhibition Of Human Antigen R Expression For Treatment of Cancer | |
| Miller | Delivery of RNAi therapeutics: work in progress | |
| Manikkath et al. | Nanoparticulate strategies for the delivery of miRNA mimics and inhibitors in anticancer therapy and its potential utility in oral submucous fibrosis | |
| US12016930B2 (en) | Skin-permeating carrier containing nucleic acid complex and use thereof | |
| Li et al. | Combinatorial synthesis and high-throughput screening of alkyl amines for nonviral gene delivery | |
| CN105073141A (zh) | 用于将基因递送到细胞的功能化dna树状聚合物 | |
| Paul et al. | The promising therapeutic potential of oligonucleotides for pulmonary fibrotic diseases |